Potential predictive value of plasma heat shock protein 90α in lung cancer

被引:8
作者
Li, Xiaoqian [1 ,2 ,3 ]
Tong, Xuesong [4 ]
Liu, Bin [5 ]
Li, Zeng [5 ]
Ding, Jing [5 ]
Li, Jiang [5 ]
Zheng, Min [5 ]
Tian, Yuke [5 ]
Yan, Siyou [5 ]
Huang, Meiling [5 ]
Ge, Jun [5 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[2] State Key Lab Oncol Southern China, Guangzhou, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Chengdu Publ Secur Bur, Pidu Branch, Criminal Sci & Technol Off Criminal Police Brigad, Chengdu, Peoples R China
[5] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Med Oncol, 55,Sect 4,Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China
关键词
HSP90; INHIBITOR; EXPRESSION; RESISTANCE; CHINA;
D O I
10.1177/03000605211064393
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: Heat shock protein 90 alpha (HSP90 alpha) is associated with cancer development, progression, and metastasis. This study assessed the relationships of plasma HSP90 alpha levels with treatment efficacy and prognosis in lung cancer. Methods: In this retrospective cross-sectional study, 231 patients with lung cancer were enrolled from 1 September 2016 to 31 December 2019. HSP90 alpha levels were measured before and after treatment, and their relationships with outcomes were assessed. Results: Patients with elevated HSP90 alpha levels before treatment had a better overall response rate (ORR, 44.1% vs. 30.6%), whereas the disease control rate did not differ between patients with elevated and normal HSP90 alpha levels (81% vs. 78.5%). Median progression-free survival (PFS) was 6.9 months in patients with elevated baseline HSP90 alpha levels, versus 9 months in patients with normal HSP90 alpha levels, whereas the median overall survival (OS) times in these groups were 12 and 14.1 months, respectively. Concerning HSP90 alpha levels after treatment, ORR (20% vs. 47.1%) and DCR (67.3% vs. 90.9%) were lower in patients with increased HSP90 alpha levels, and PFS and OS were also significantly different between the groups. Conclusions: HSP90 alpha levels before and after treatment were associated with treatment response and patient prognosis in lung cancer.
引用
收藏
页数:9
相关论文
共 27 条
  • [1] Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
    Arbour, Kathryn C.
    Riely, Gregory J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08): : 764 - 774
  • [2] Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer
    Bao, Rudi
    Lai, Cheng-Jung
    Wang, Da-Gong
    Qu, Hui
    Yin, Ling
    Zifcak, Brian
    Tao, Xu
    Wang, Jing
    Atoyan, Ruzanna
    Samson, Maria
    Forrester, Jeffrey
    Xu, Guang-Xin
    DellaRocca, Steven
    Borek, Mylissa
    Zhai, Hai-Xiao
    Cai, Xiong
    Qian, Changgeng
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) : 3296 - 3306
  • [3] Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
    Cedres, Susana
    Felip, Enriqueta
    Cruz, Cristina
    Martinez de Castro, Ana
    Pardo, Nuria
    Navarro, Alejandro
    Martinez-Marti, Alex
    Remon, Jordin
    Zeron-Medina, Jorge
    Balmana, Judith
    Llop-Guevara, Alba
    Miquel, Josep M.
    Sansano, Irene
    Nuciforo, Paolo
    Mancuso, Francesco
    Serra, Violeta
    Vivancos, Ana
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (08): : 914 - 917
  • [4] Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network
    Chatterjee, Suman
    Huang, Eric H. -B.
    Christie, Ian
    Kurland, Brenda F.
    Burns, Timothy F.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (05) : 793 - 804
  • [5] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [6] Annual report on status of cancer in China, 2010
    Chen, Wanqing
    Zheng, Rongshou
    Zhang, Siwei
    Zhao, Ping
    Zeng, Hongmei
    Zou, Xiaonong
    He, Jie
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) : 48 - 58
  • [7] Secreted Heat Shock Protein 90α (HSP90α) Induces Nuclear Factor-κB-mediated TCF12 Protein Expression to Down-regulate E-cadherin and to Enhance Colorectal Cancer Cell Migration and Invasion
    Chen, Wei-Shone
    Chen, Chia-Chi
    Chen, Li-Li
    Lee, Chun-Chung
    Huang, Tze-Sing
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (13) : 9001 - 9010
  • [8] Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations
    Dai, Juncheng
    Zhu, Meng
    Wang, Yuzhuo
    Qin, Na
    Ma, Hongxia
    He, Yong-Qiao
    Zhang, Ruoxin
    Tan, Wen
    Fan, Jingyi
    Wang, Tianpei
    Zheng, Hong
    Sun, Qi
    Wang, Lijuan
    Huang, Mingtao
    Ge, Zijun
    Yu, Canqing
    Guo, Yu
    Wang, Tong-Min
    Wang, Jie
    Xu, Lin
    Wu, Weibing
    Chen, Liang
    Bian, Zheng
    Walters, Robin
    Millwood, Iona Y.
    Li, Xi-Zhao
    Wang, Xin
    Hung, Rayjean J.
    Christiani, David C.
    Chen, Haiquan
    Wang, Mengyun
    Wang, Cheng
    Jiang, Yue
    Chen, Kexin
    Chen, Zhengming
    Jin, Guangfu
    Wu, Tangchun
    Lin, Dongxin
    Hu, Zhibin
    Amos, Christopher I.
    Wu, Chen
    Wei, Qingyi
    Jia, Wei-Hua
    Li, Liming
    Shen, Hongbing
    [J]. LANCET RESPIRATORY MEDICINE, 2019, 7 (10) : 881 - 891
  • [9] Immunotherapy and lung cancer: current developments and novel targeted therapies
    Domingues, Duarte
    Turner, Alice
    Silva, Maria Dilia
    Marques, Dania Sofia
    Mellidez, Juan Carlos
    Wannesson, Luciano
    Mountzios, Giannis
    de Mello, Ramon Andrade
    [J]. IMMUNOTHERAPY, 2014, 6 (11) : 1221 - 1235
  • [10] Sixty Years of CA: A Cancer Journal for Clinicians
    Gansler, Ted
    Ganz, Patricia A.
    Grant, Marcia
    Greene, Frederick L.
    Johnstone, Peter
    Mahoney, Martin
    Newman, Lisa A.
    Oh, William K.
    Thomas, Charles R., Jr.
    Thun, Michael J.
    Vickers, Andrew J.
    Wender, Richard C.
    Brawley, Otis Webb
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2010, 60 (06) : 345 - 350